Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.
Articles
Field Trip Health Ltd. Reports Fiscal Fourth Quarter and Full Year 2021 Financial Results
Field Trip reports Q4 and full-year results for fiscal 2021. Cash position of CAD$111m. Clinic revenues increased by 63% q-o-q to CAD$526,435.
Numinus Files U.S. Provisional Patent Application for a Proprietary Rapid Production Process for Psilocybe and Other Psychoactive Fungi Species
Numinus files a patent application for a "process" that can allow faster, more cost-effective production of psychoactive compounds such as psilocybin.
House Committee Approves Marijuana Protections For Banking And D.C.
A House subcommittee on Thursday approved a large-scale funding bill that includes provisions protecting banks from being punished for working with marijuana businesses and allowing Washington, D.C. to legalize cannabis sales.
Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004
Mydecine's novel molecule, MYCO-004 is targeting multiple forms of addiction/substance abuse.
Cybin Announces Former FDA Psychiatry Division Director Dr. Thomas Laughren has Joined Clinical Advisory Board
The newest member of Cybin's Clinical Advisory Board previously held a senior position with the FDA.
Alternatives to ATAI: Go Big Or Go Small?
Sometimes biggest is not "best". Psychedelic Stock Watch offers investors a lot of reasons why thinking SMALLER may be more profitable.
Novamind Welcomes Dr. Paul Thielking as Chief Scientific Officer
Novamind's new Chief Scientific Officer is a physician with deep knowledge of psychiatry and palliative care, including familiarity with ketamine-assisted psychotherapy.
Roth Initiates Coverage On Mydecine Innovations With A 9x Price Target
Investors of Mydecine Innovations Group received a pleasant surprise Tuesday morning, drawing coverage from a firm that is making itself known in the psychedelics industry.
Microdosing LSD modulates the perception of time independently of other consciousness-altering effects
Lysergic acid diethylamide, or LSD, is a drug which produces a variety of cognitive, perceptual and behavioral changes in users.
Rhode Island Senate Approves Marijuana Legalization Bill
The Rhode Island Senate on Tuesday approved a bill to legalize marijuana.
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
Cybin completes its 51st pre-clinical molecule study, with four of these molecules already being advanced to toward clinical evaluations.
Western Illinois University Graduates First Cannabis & Culture Minor
The first of five Western Illinois University students with a minor in Cannabis & Culture was part of the school’s spring 2021 graduating class.
‘NJ Weedman’ Running for Governor with Write-In Campaign
Edward Forchion, the cannabis advocate known as “NJ Weedman,” is running a write-in campaign for New Jersey governor following a successful challenge of his nominating petitions by the Democratic State Committee, NJ.com reports.
Maine Lawmakers Vote to Decriminalize All Drugs
Possession of illicit drugs like heroin and cocaine could be decriminalized in Maine, following two favorable votes by lawmakers last week.